Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval

2026-03-13 12:05:48 ET

Investment Overview

Mineralys Therapeutics, Inc. ( MLYS ), the Radnor Pennsylvania based biotech focused on the development of lorundrostat - an orally administered aldosterone synthase inhibitor ("ASI") indicated for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities such as chronic kidney disease ("CKD") and obstructive sleep apnea ("OSA") - announced its Q4 and full-year 2025 financial results and provided business updates yesterday....

Read the full article on Seeking Alpha

For further details see: